<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345826</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000480396</org_study_id>
    <secondary_id>UCLA-0509010-01</secondary_id>
    <secondary_id>BMS-CA180039</secondary_id>
    <nct_id>NCT00345826</nct_id>
  </id_info>
  <brief_title>Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Long-Term Safety and Efficacy of Dasatinib (BMS-354825) in Subjects Who Experienced Clinical Benefit on Protocol CA 180-002</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Dasatinib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of dasatinib in treating patients&#xD;
      with chronic myelogenous leukemia or acute lymphoblastic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the long-term safety and tolerability of dasatinib in patients with&#xD;
           Philadelphia chromosome-positive chronic myelogenous leukemia or acute lymphoblastic&#xD;
           leukemia resistant or intolerant to imatinib mesylate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Describe any hematologic or cytogenetic response in patients treated with this drug.&#xD;
&#xD;
        -  Determine the duration of hematologic and cytogenetic response in patients using this&#xD;
           drug during trial UCLA-0303035.&#xD;
&#xD;
        -  Determine the progression-free survival and overall survival of patients treated with&#xD;
           this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, roll-over study of protocol UCLA-0303035.&#xD;
&#xD;
      Patients receive oral dasatinib once or twice daily for 5, 6, or 7 days. Treatment repeats&#xD;
      every 7 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 54 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long term safety and tolerability</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <arm_group_label>Dasatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of one of the following hematologic malignancies:&#xD;
&#xD;
               -  Chronic phase chronic myelogenous leukemia (CML)&#xD;
&#xD;
                    -  In complete hematologic response after treatment on protocol UCLA-0303035,&#xD;
                       as indicated by the following criteria:&#xD;
&#xD;
                         -  WBC ≤ upper limit of normal (ULN)&#xD;
&#xD;
                         -  Platelet count &lt; 450,000/mm^3&#xD;
&#xD;
                         -  No blasts or promyelocytes in peripheral blood&#xD;
&#xD;
                         -  Less than 5% myelocytes plus metamyelocytes in peripheral blood&#xD;
&#xD;
                         -  Peripheral blood basophils ≤ ULN&#xD;
&#xD;
                         -  No extramedullary involvement (including no hepatomegaly or&#xD;
                            splenomegaly)&#xD;
&#xD;
                         -  Response lasting ≥ 4 weeks after first documentation&#xD;
&#xD;
               -  Accelerated or blastic phase CML or acute lymphoblastic leukemia&#xD;
&#xD;
                    -  In major hematologic response* after treatment on protocol UCLA-0303035,&#xD;
                       defined as 1 of the following:&#xD;
&#xD;
                         -  In complete hematologic response*, as indicated by the following&#xD;
                            criteria:&#xD;
&#xD;
                              -  WBC ≤ ULN&#xD;
&#xD;
                              -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
                              -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
                              -  No blasts or promyelocytes in peripheral blood&#xD;
&#xD;
                              -  Bone marrow blasts ≤ 5%&#xD;
&#xD;
                              -  Less than 5% myelocytes plus metamyelocytes in peripheral blood&#xD;
&#xD;
                              -  Peripheral blood basophils ≤ ULN&#xD;
&#xD;
                              -  No extramedullary involvement (including no hepatomegaly or&#xD;
                                 splenomegaly)&#xD;
&#xD;
                         -  No evidence of leukemia, as indicated by the following criteria:&#xD;
&#xD;
                              -  WBC ≤ ULN&#xD;
&#xD;
                              -  No blasts or promyelocytes in the peripheral blood&#xD;
&#xD;
                              -  Bone marrow blasts ≤ 5%&#xD;
&#xD;
                              -  Less than 5% myelocytes plus metamyelocytes in peripheral blood&#xD;
&#xD;
                              -  Peripheral blood basophils ≤ ULN&#xD;
&#xD;
                              -  No extramedullary involvement (including no hepatomegaly or&#xD;
                                 splenomegaly)&#xD;
&#xD;
                              -  Absolute neutrophil count ≥ 500/mm^3 and &lt; 1,000/mm^3 AND platelet&#xD;
                                 count ≥ 20,000/mm^3 and &lt; 100,000/mm^3&#xD;
&#xD;
                    -  In minor hematologic response* after treatment on protocol UCLA-0303035, as&#xD;
                       indicated by the following criteria:&#xD;
&#xD;
                         -  Less than 15% in bone marrow and &lt; 15% in peripheral blood&#xD;
&#xD;
                         -  Less than 30% blasts plus promyelocytes in bone marrow and &lt; 30% blasts&#xD;
                            plus promyelocytes in peripheral blood&#xD;
&#xD;
                         -  Less than 20% basophils in peripheral blood&#xD;
&#xD;
                         -  No extramedullary disease other than spleen and liver NOTE: *Response&#xD;
                            confirmed after ≥ 4 weeks allowed provided there is no concurrent&#xD;
                            anagrelide or hydroxyurea during this time&#xD;
&#xD;
          -  Philadelphia chromosome-positive (Ph+) disease&#xD;
&#xD;
          -  Resistant or intolerant to prior imatinib mesylate&#xD;
&#xD;
          -  Received and benefitted from ≥ 3 months of prior therapy with dasatinib on protocol&#xD;
             UCLA-0303035&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 weeks after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No serious uncontrolled medical disorder&#xD;
&#xD;
          -  No active infection that would preclude study participation&#xD;
&#xD;
          -  No uncontrolled angina within the past 3 months&#xD;
&#xD;
          -  No diagnosed or suspected congenital long QT syndrome&#xD;
&#xD;
          -  No history of clinically significant ventricular arrhythmias (e.g., ventricular&#xD;
             tachycardia, ventricular fibrillation, or torsades de pointes)&#xD;
&#xD;
          -  QTc ≤ 450 msec on electrocardiogram&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No dementia or altered mental status the would prohibit the understanding or rendering&#xD;
             of informed consent&#xD;
&#xD;
          -  No history of the following significant bleeding disorders unrelated to CML:&#xD;
&#xD;
               -  Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)&#xD;
&#xD;
               -  Diagnosed acquired bleeding disorder in the past year (e.g., acquired antifactor&#xD;
                  VIII antibodies)&#xD;
&#xD;
          -  Not involuntarily incarcerated for either psychiatric or physical (e.g., infectious&#xD;
             disease) illness&#xD;
&#xD;
          -  No patients who are imprisoned&#xD;
&#xD;
          -  No clinical adverse event, laboratory abnormality, or intercurrent illness that may&#xD;
             preclude study treatment, in the opinion of the investigator&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  ALT and AST &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent use of the following drugs that may confer risk of torsades de pointes:&#xD;
&#xD;
               -  Quinidine&#xD;
&#xD;
               -  Procainamide&#xD;
&#xD;
               -  Disopyramide&#xD;
&#xD;
               -  Amiodarone&#xD;
&#xD;
               -  Sotalol&#xD;
&#xD;
               -  Ibutilide&#xD;
&#xD;
               -  Dofetilide&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Chlorpromazine&#xD;
&#xD;
               -  Haloperidol&#xD;
&#xD;
               -  Mesoridazine&#xD;
&#xD;
               -  Thioridazine&#xD;
&#xD;
               -  Pimozide&#xD;
&#xD;
               -  Cisapride&#xD;
&#xD;
               -  Bepridil&#xD;
&#xD;
               -  Droperidol&#xD;
&#xD;
               -  Methadone&#xD;
&#xD;
               -  Arsenic&#xD;
&#xD;
               -  Chloroquine&#xD;
&#xD;
               -  Domperidone&#xD;
&#xD;
               -  Halofantrine&#xD;
&#xD;
               -  Levomethadyl&#xD;
&#xD;
               -  Pentamidine&#xD;
&#xD;
               -  Sparfloxacin&#xD;
&#xD;
               -  Lidoflazine&#xD;
&#xD;
          -  No other concurrent treatment for CML except for hydroxyurea for a 2-week duration&#xD;
&#xD;
          -  No concurrent medications that inhibit platelet function (e.g., aspirin, dipyridamole,&#xD;
             epoprostenol, eptifibatide, clopidogrel, cilostazol, abciximab, ticlopidine, or any&#xD;
             nonsteroidal anti-inflammatory drug)* except for hydroxyurea or anagrelide&#xD;
&#xD;
          -  No concurrent anticoagulants (e.g., warfarin or heparin/low molecular weight heparin&#xD;
             [e.g., danaparoid, dalteparin, tinzaparin, or enoxaparin]) except as prophylaxis for&#xD;
             catheter thrombosis and/or heparin flushes for IV lines* NOTE: *Allowed if received&#xD;
             previously on UCLA-0303035&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Sawyers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41.</citation>
    <PMID>16775234</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 28, 2006</study_first_submitted>
  <study_first_submitted_qc>June 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2006</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>chronic myelogenous leukemia, BCR-ABL1 positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

